UNSPSC 51413600: Vasodilator pyrimidines

Vasodilator drugs made from a family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms.

UNSPSC 51413600 Vasodilator pyrimidines is a Class code that classifies pharmaceutical active ingredients and finished medications used in emergency medical response and state pharmacy benefit programs. State and local governments procure these medications for emergency medical services, fire rescue operations, and pharmacy benefit management serving state employees and Medicaid beneficiaries. Solicitations under this code span municipal fire departments (Tampa Fire Rescue) and state health and human services agencies (Texas HHS Commission), with purchasing activity driven by operational need for emergency pharmaceuticals and strategic sourcing initiatives to manage pharmacy costs across state and local health systems. The scope includes finished injectable medications such as epinephrine, adenosine, diltiazem, and labetalol—all critical advanced life support agents—as well as broader generic pharmaceutical sourcing through cooperative purchasing alliances.

Recent activity is concentrated in Texas and Florida, with multistate cooperative purchasing frameworks adding reach across participating jurisdictions including Minnesota and Oregon. The City of Tampa issued an IFB (Solicitation 26P00188) in April 2026 seeking 370 units of labetalol and other ALS medications for Tampa Fire Rescue with a due date of April 8, 2026 and estimated contract value of $40,000, with a one-year term and two optional one-year renewals plus unilateral extension authority for up to three additional 30-day periods. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in March 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, indicating strategic exploration of pharmacy supply chain redesign outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued an RFP in January 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a due date of March 26, 2026 and an effective date of July 1, 2026, requiring vendor participation through authorized wholesalers and a two-year contract term. The code shows active procurement demand with emphasis on cost competitiveness, supply chain security compliance (DSCSA, cGMP), and direct-to-wholesaler distribution relationships.